Myles Minter

Stock Analyst at William Blair

(2.64)
# 2,356
Out of 5,182 analysts
25
Total ratings
57.89%
Success rate
15.71%
Average return

Stocks Rated by Myles Minter

Korro Bio
Feb 17, 2026
Upgrades: Outperform
Price Target: n/a
Current: $14.28
Upside: -
Neumora Therapeutics
Feb 17, 2026
Upgrades: Outperform
Price Target: n/a
Current: $2.19
Upside: -
Biohaven
Nov 5, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $10.82
Upside: -
Alector
Oct 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.71
Upside: -
Dianthus Therapeutics
Jul 2, 2025
Initiates: Outperform
Price Target: n/a
Current: $91.92
Upside: -
Immunic
Mar 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.96
Upside: -
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.52
Upside: -
argenx SE
Nov 1, 2024
Upgrades: Outperform
Price Target: n/a
Current: $834.45
Upside: -
Arcturus Therapeutics Holdings
Jul 24, 2023
Initiates: Outperform
Price Target: $71
Current: $8.90
Upside: +697.75%
Moderna
Jul 24, 2023
Initiates: Market Perform
Price Target: n/a
Current: $54.59
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $439.18
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $342.57
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $4.81
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $310.94
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $74.87
Upside: -
Initiates: Outperform
Price Target: $116
Current: $131.59
Upside: -11.85%